Related Experiment Videos
Changes in hepatic folylpolyglutamate pattern in phenobarbitone-treated rats.
C Bovina1, G Formiggini, M Battino
1Department of Biochemistry, University of Bologna, Italy.
Biochemical Pharmacology
|June 15, 1990
Summary
Anticonvulsant drugs like phenobarbitone can cause folate deficiency by altering liver folate metabolism. This study suggests reduced NADPH availability limits folate reduction, contributing to this common side effect.
Area of Science:
- Biochemistry
- Pharmacology
- Nutritional Science
Background:
- Folate deficiency is a frequent adverse effect of anticonvulsant medications.
- Understanding the biochemical pathways is crucial for managing this condition.
Purpose of the Study:
- To investigate the impact of acute phenobarbitone administration on hepatic folate derivatives in rats.
- To elucidate the biochemical mechanisms underlying anticonvulsant-induced folate deficiency.
Main Methods:
- Acute treatment of rats with high doses of phenobarbitone via intraperitoneal injection.
- Analysis of the distribution of hepatic folate derivatives post-treatment.
Main Results:
- Significant reduction in unsubstituted tetrahydro- and dihydropteroylpentaglutamates.
- Observed decrease in 5,10-methylenetetrahydropentaglutamates.
- Indicates altered folate metabolism following phenobarbitone exposure.
Conclusions:
- Phenobarbitone treatment significantly affects hepatic folate derivative levels.
- A potential mechanism involves reduced NADPH availability limiting folate reduction.
- This contributes to the understanding of folate deficiency associated with anticonvulsant therapy.